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Abstract
 
The recognition of antigen by membrane immunoglobulin M (mIgM) results in a complex se-
ries of signaling events in the cytoplasm leading to gene activation. Bruton’s tyrosine kinase
(BTK), a member of the Tec family of tyrosine kinases, is essential for the full repertoire of
IgM signals to be transduced. We examined the ability of BTK to regulate the nuclear factor
(NF)-
 
k
 
B/Rel family of transcription factors, as the activation of these factors is required for a B
cell response to mIgM. We found greatly diminished IgM- but not CD40-mediated NF-
 
k
 
B/
Rel nuclear translocation and DNA binding in B cells from X-linked immunodeficient (xid)
mice that harbor an R28C mutation in 
 
btk
 
, a mutation that produces a functionally inactive ki-
nase. The defect was due, in part, to a failure to fully degrade the inhibitory protein of NF-
 
k
 
B,
I
 
k
 
B
 
a
 
. Using a BTK-deficient variant of DT40 chicken B cells, we found that expression of
wild-type or gain-of-function mutant BTK, but not the R28C mutant, reconstituted NF-
 
k
 
B
activity. Thus, BTK is essential for activation of NF-
 
k
 
B via the B cell receptor.
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Introduction
 
Mutation of the gene encoding Bruton’s tyrosine kinase
 
(BTK)
 
1
 
 causes X-linked immunodeficiency (xid) in mice
and X-linked agammaglobulinemia (XLA) in humans (1, 2,
2a). XLA patients exhibit a block in early B cell maturation
that prevents development of antibody-producing cells (3).
 
btk
 
 mutation in mice reduces peripheral B cells to 
 
,
 
50% of
wild-type levels and renders them unresponsive to T-inde-
pendent type II antigens without preventing responses to
T-independent type I or T-dependent antigens (4). Xid
mice also have low serum IgM and IgG3 and no peritoneal
 
CD5
 
1
 
 B-1a cells (4). Different mutations spanning the hu-
man 
 
btk
 
 gene result in XLA, whereas in mice, a single mis-
sense mutation of BTK, R28C, results in x-linked immuno-
deficiency. This led to speculation that the severity of the
human phenotype was due to the location of the mutation
in the 
 
btk
 
 gene. Further experimentation showed that dis-
ruption of the 
 
btk
 
 gene in mice also produced the xid phe-
notype (5, 6). Conversely, patients with the single basepair
mutation producing the R28C amino acid replacement re-
tained the severity of the human disease (7). Together, these
data showed that the xid mutation renders mice deficient in
essential BTK functions and that the B cell requirement for
BTK differs between the murine and human species.
Expression of BTK is limited to B, mast, and myeloid
cells. BTK, like other members of the Tec family of cyto-
plasmic tyrosine kinases, is similar to the Src family kinases
in that it contains Src homology (SH)1, SH2, and SH3 do-
mains. However, Tec family members lack the NH
 
2
 
-ter-
minal myristylation site and COOH-terminal negative reg-
ulatory site found in the Src family kinases. In addition,
they have a unique region, termed the Tec homology do-
main, and an NH
 
2
 
-terminal pleckstrin homology (PH) do-
main (for review see reference 8). BTK is expressed contin-
uously from the late pro-B stage up to the plasma cell stage
(9). Loss of BTK function disrupts signaling through the
IL-5R, CD38, IL-10R, Fc
 
e
 
RI, and B cell receptor for an-
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Abbreviations used in this paper:
 
 BCR, B cell receptor for antigen; BTK,
Bruton’s tyrosine kinase; EMSAs, electrophoretic mobility shift assays;
GFP, green fluorescent protein; mIgM, membrane IgM; NF-
 
k
 
B, nuclear
factor 
 
k
 
B; PH, pleckstrin homology; PKC, protein kinase C; PLC-
 
g
 
2,
phospholipase C
 
g
 
2; SH, Src homology; xid, X-linked immunodefi-
ciency; XLA, X-linked agammaglobulinemia. 
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tigen (BCR) pathways (10–15). In mature B cells, BTK is
tyrosine phosphorylated upon membrane IgM receptor
cross-linking (16, 17). In fibroblasts, ectopic expression of
Lyn leads to transphosphorylation of BTK at Tyr-551 (18).
The kinase responsible for this phosphorylation in B cells
has not been identified. Phosphorylation at Tyr-551 leads
to BTK autophosphorylation at Tyr-223, membrane local-
ization, and increased kinase activity (19). The PH domain
of BTK has a high affinity for phosphoinositide phospho-
lipids, in particular phosphatidylinositol (PI)-3,4,5-triphos-
phate (PtdIns-3,4,5-P
 
3
 
) (20). PtdIns-3,4,5-P
 
3 
 
binding is
necessary for the activation-dependent membrane localiza-
tion of BTK (18, 21). In addition, several proteins have
been reported to bind BTK: transcription factor II-I (TFII-I
[BAP-135]), protein kinase C (PKC) isoforms, Wiskott-
Aldrich syndrome protein (WASP), Ewing’s sarcoma pro-
tein (EWS), cbl, SAM68 (Src-associated in mitosis 68 kD),
SLP-65 (SH2 domain–containing linker protein 65 kD;
BLNK [B cell linker protein]), and vav (22–27). BTK is
critical for the activation of phospholipase (PLC)-
 
g
 
2, lead-
ing to intracellular calcium release, extracellular calcium in-
flux, and PKC activation (28–30).
Wild-type B cells enter cell cycle upon antigen cross-
linking of the BCR, whereas xid, or 
 
btk
 
2
 
/
 
2
 
, cells undergo
apoptosis. Although IgM cross-linking of xid B cells does
not lead to proliferation, some IgM-mediated signals are
successfully transmitted, resulting in upregulation of MHC
class II and tyrosine phosphorylation of multiple proteins
(29, 31). Further downstream, uncharacterized BTK-depen-
dent pathways lead to Bcl-x
 
L
 
 (32) and cyclin induction
(33). This suggested that IgM-mediated transcription factor
activation is compromised in xid B cells.
In primary splenic B cells, IgM cross-linking or CD40 li-
gation leads to nuclear translocation and DNA binding of
the NF-
 
k
 
B/Rel family of transcription factors (34–36).
Phenotypic analysis of mice deficient in individual NF-
 
k
 
B/
Rel family members has demonstrated the essential role of
these transcription factors in CD40, LPS, and IgM receptor
pathways leading to B cell proliferation. In particular, B
cells from mice deficient in NF-
 
k
 
B members 
 
c-rel
 
 or 
 
p65
 
have decreased responses to antigen cross-linking (37, 38).
 
C-rel
 
2
 
/
 
2
 
 
 
B cells also failed to respond to CD40 ligation (not
determined in 
 
p65
 
2
 
/
 
2
 
 mice). Recently, an examination of
B cells in mice expressing a transdominant form of I
 
k
 
B
 
a
 
revealed xid-like defects, including a lack of proliferation in
response to anti-IgM (39). The CD40 transduction of NF-
 
k
 
B activation has been well characterized (40–42). There is
less information about the molecular signaling events con-
necting the BCR to NF-
 
k
 
B activation.
Recently, several of the events proximal to NF-
 
k
 
B acti-
vation have been elucidated (for review see reference 43).
In wild-type resting cells, NF-
 
k
 
B/Rel factors are seques-
tered in the cytoplasm by members of the inhibitory 
 
k
 
B
(I
 
k
 
B) family of proteins. Activation of I
 
k
 
B kinases results in
serine/threonine phosphorylation, subsequent ubiquitina-
tion, and the proteolytic degradation of I
 
k
 
B. The nuclear
localization sequence of the NF-
 
k
 
B/Rel proteins is then
exposed, and the factors localize to the nucleus.
 
As BTK and NF-
 
k
 
B are both essential for normal B cell
function, we asked whether BTK might be involved in
NF-
 
k
 
B activation. We compared wild-type and xid mu-
rine B cells with respect to BCR-mediated induction of
NF-
 
k
 
B DNA binding, nuclear translocation, transcript in-
duction, and I
 
k
 
B degradation. Reconstitution experiments
in the BTK-deficient variant of the chicken B cell line
DT40 allowed us to determine the effect of wild-type and
mutant BTK proteins on NF-
 
k
 
B activation.
 
Materials and Methods
 
Preparation and Activation of Splenic Murine B Cells.
 
A BALB/
cAnN-xid colony was generated from original breeding pairs de-
rived from BALB/cAnN-xid mice provided by Dr. C. Hansen
(National Institutes of Health Genetic Resource Center, Be-
thesda, MD) and maintained at Tufts University. BALB/cByJ
mice were obtained from The Jackson Laboratory. Splenic B cells
were isolated from 
 
.
 
8-wk-old mice by complement-mediated T
cell lysis as previously described (44). This procedure was modi-
fied by addition of a Lympholyte-M Ficoll (Cedarlane) gradient
step after treatment with Tris-ammonium chloride–BSA to re-
move residual RBCs in the lymphocyte populations. Cell popu-
lations were 90–99% splenic B cells, as tested by FACS
 
®
 
 analysis
for CD45 (B220) expression.
Cells were pelleted and resuspended for culture at 10
 
6
 
 cells/ml
in RPMI 1640 (Life Technologies) containing 10% heat-inacti-
vated FCS, 20 mM Hepes, pH 7.0, 1 mM sodium pyruvate, 0.1
mM nonessential amino acids, 100 U/ml penicillin, 100 mg/ml
streptomycin sulfate, and 50 mM 2-ME (called complete medium
below). In all assays, cells were left untreated or treated for 4 h
with 10 
 
m
 
g/ml F(ab
 
9
 
)
 
2
 
 goat anti–mouse IgM, 
 
m
 
 chain specific
(Jackson ImmunoResearch), hybridoma supernatant CD8/CD40L
(45) protein at a final dilution of 1:2, or PMA (Sigma-Aldrich)
and ionomycin (Sigma-Aldrich) at a final concentration of 30 nM
and 1 mM, respectively. (Preliminary time course experiments
demonstrated maximal translocation of nuclear c-rel after stimu-
lation for 4 h.) In some experiments, cells were assayed for early
signs of apoptosis after B cell stimulation for 4 h, as described
(46).
 
Cell Lines and Constructs.
 
DT40 wild-type and BTK-defi-
cient chicken B cell lines were generated by Dr. T. Kurosaki
(Kansai University, Kansai, Japan) and provided by Dr. J.
Ravetch (The Rockefeller University, New York, NY). The
cells were maintained in culture at a density of 
 
,
 
5 
 
3 
 
10
 
5
 
 cells/ml
in complete medium, with the addition of 1% heat-inactivated
chicken serum. These cells were stimulated (in the absence of
chicken serum) with 10 
 
m
 
g/ml mouse monoclonal anti–chicken
IgM, M4 (generated by Dr. M. Cooper, University of Alabama,
Birmingham, AL and obtained from Dr. E. Clark, Washington
University, St. Louis, MO), or 30 nM PMA (Sigma-Aldrich) in
combination with 1 
 
m
 
M ionomycin (Sigma-Aldrich). WEHI231
and T220 cell lines were cultured in complete medium.
The pGD-BTK construct was provided by Dr. G. Cheng
(University of California at Los Angeles, Los Angeles, CA).
R28C (xid) and E41K (gain-of-function) basepair mutations
were generated in the murine 
 
btk 
 
gene by standard PCR mu-
tagenesis and checked by sequence analysis at the Tufts University
Sequencing Facility. The wild-type and mutant 
 
btk
 
 cDNAs were
excised from the pGD vector by XhoI and NotI digestion and in-
serted into EcoRI-linearized pBabeApuro vector, which was do-
nated by Dr. T. Kurosaki (47). 
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The luciferase reporter constructs, containing three NF-
 
k
 
B
DNA binding sites or lacking these sites, were provided by Dr.
S. Ghosh (Yale University, New Haven, CT). A pRLTK con-
struct (Promega) served as an internal control in the luciferase
experiments.
 
Electrophoretic Mobility Shift Assays.
 
4 
 
3 
 
10
 
7
 
 cells were stimu-
lated, as described above, and nuclear extracts were prepared as
previously described (48). The 
 
k
 
B site used as a probe in this assay
is a 70-bp fragment excised from a plasmid containing the H2K
MHC gene promoter (49). The fragment was labeled with
 
g
 
-[
 
32
 
P]dATP (Dupont) by T4 polynucleotide kinase. 5 
 
m
 
g of nu-
clear protein or the equivalent of 4 
 
3 
 
10
 
6
 
 cells was incubated
with 10,000 cpm of the NF-
 
k
 
B probe. Electrophoretic mobility
shift assays (EMSAs) were performed as described (48).
 
[
 
35
 
S]Methionine/Cysteine Pulse–Chase Experiments.
 
For each
treatment, 2 
 
3 
 
10
 
7
 
 splenic B cells were cultured in 2 ml of cys-
teine- and methionine-free RPMI (BioWhittaker), containing
10% dialyzed FCS (JRH Bioscience), for 2 h at 37
 
8
 
C. These cys-
teine- and methionine-deprived cells were then incubated for an
additional 2 h with 60 
 
m
 
Ci/ml 
 
35
 
S-labeled cysteine and methio-
nine at 37
 
8
 
C. Cells were pelleted and resuspended in 2 ml of 10%
FCS, complete medium and cultured for 0 or 1 h at 37
 
8
 
C, with
or without F(ab
 
9
 
)
 
2
 
 goat anti–mouse IgM (described above). After
treatment, the cells were lysed in 1 ml TNTE buffer (50) for a
minimum of 0.5 h. Nuclear and membrane debris was pelleted by
centrifugation at 16,000 
 
g
 
 for 10 min at 4
 
8
 
C. The supernatant
lysate was precleared by incubation with Sepharose A beads (Amer-
sham Pharmacia Biotech) and 28 
 
m
 
g of whole rabbit IgG (Sigma-
Aldrich) for 45 min at 4
 
8
 
C. These precleared lysates were incu-
bated overnight with Sepharose A beads and 60 
 
m
 
g of anti-I
 
k
 
B
 
a
 
antibody (SC-371; Santa Cruz Biotechnology). The I
 
k
 
B
 
a-bound
beads were washed four times with lysis buffer at 48C. 100 ml of
l% SDS-TNTE lysis buffer was added to the washed beads, and
samples were boiled for 5 min. 900 ml of TNTE lysis buffer was
added, the beads were pelleted, and the IkBa-containing lysate
was transferred to a new tube. To reduce the background, the
IkBa immunoprecipitation was repeated. The beads were washed
four times with lysis buffer, and 50 ml of 23 Laemmli buffer was
added to the pelleted beads. The samples were then electropho-
resed on 10% SDS-PAGE for 3 h at 30 mA. The gel was fixed for
10 min with a 10% acetic acid/50% methanol solution. After
multiple washes in water, the gel was placed in a 1 M salicylic
acid/1% glycerol solution for 30 min, rinsed quickly with water,
and dried at 508C for 2 h. The dried gel was exposed in a Phos-
phorImager (Molecular Dynamics) overnight. Densitometry anal-
ysis was carried out using the Bio-Rad Imaging Densitometer and
Multi-Analysis Software (Bio-Rad Laboratories).
Western Blot Analysis. Nuclear and cytoplasmic extracts were
prepared from wild-type and xid B cells as previously described
(48). During this lysis procedure, the buffer A supernatant was
saved, as it contained the cytoplasmic proteins. Whole cell ex-
tracts were prepared by lysis of 107 cells in 13 Laemmli buffer.
Samples from equivalent micrograms or cell numbers were elec-
trophoresed on 10% SDS-PAGE for 3 h at 30 mA. Proteins were
transferred to immobilon P membranes (Millipore). The mem-
branes were blocked with 5% milk/0.1%BSA–DPBS for 45 min
at room temperature. Membranes that were to be stained with
anti-BTK serum were blocked with 5% BSA in TBST (contain-
ing 0.1% BSA and 0.1% Tween). The membranes were incu-
bated for 1.5 h at room temperature with anti–c-rel at 1:500 dilu-
tion (SC-071; Santa Cruz Biotechnology), anti-IkBa at 1:1,000
dilution (SC-371; Santa Cruz Biotechnology), anti–SP-1 at 1:500
dilution (SC-420; Santa Cruz Biotechnology), anti–b-actin at
1:2,500 dilution (Sigma-Aldrich), or rabbit anti–murine BTK
(amino acids 182–191) at 1:1,000 dilution. After multiple washes,
the membranes were incubated with secondary horseradish per-
oxidase–goat anti–rabbit or anti–mouse IgG (Boehringer Mann-
heim) for 45 min at room temperature and then exposed to ECL
chemiluminescence reagent (Dupont).
DT40 Transfection and Dual Luciferase Assays. A total of 30 or
50 mg of DNA was used to transfect 107 DT40 cells. Transfection
was conducted by electroporation (330 V, 250 mF). The cells
were cultured for 16–24 h at 408C and stimulated as described
above. The dual luciferase assay was performed using the
Promega dual-luciferase assay kit as described in the manufac-
turer’s instruction manual.
Northern Blot Analysis. Total RNA was isolated from 3 3 107
splenic B cells per treatment using the guanidium thiocyanate
method. In brief, 10 mg of RNA was electrophoresed on a 1%
agarose, 2.2 M formaldehyde gel and transferred to nitrocellulose
overnight, and the blot was baked for 2 h at 808C. The blot was
hybridized with a a-[32P]dCTP end-labeled c-rel cDNA,
washed, and exposed to film for 1 wk at 2708C (49). This 1.8-kb
c-rel fragment was isolated from pEVRF2-c-rel using BAMH1
and HindIII.
Reverse Transcriptase PCR Analysis. cDNA was generated
from 1 mg of total RNA (isolated as described above) using the
Superscript Preamplification System (oligo dT was used as the
primer; GIBCO BRL). 1 ml of cDNA was used in a standard
PCR reaction using primers specific for c-rel (59 primer: GCT
CCA AAT ACT GCA GAA TTA AGG; 39 primer: CGT GCA
GAT ATC TAA AAT CCA TAG) or GaS (59 primer: AAT
GAA ACC ATT GTG GCC GCC ATG AGC; 39 primer: GAA
GAC ACG GCG GAT GTT CTC AGT GTC). The conditions
for the PCR reaction were 40 cycles of 958C for 15 s, 548C for
30 s, and 728C for 1 min, and 1 cycle of 728C for 15 min.
Results
Reduced DNA Binding and Nuclear Translocation of NF-kB/
Rel Transcription Factors in IgM- but not CD40-stimulated XID
B Cells. EMSAs showed that xid, btk-mutated B cells did
not induce DNA binding of NF-kB/Rel transcription fac-
tors after treatment for 4 h with F(ab9)2 anti-IgM (Fig. 1 A).
Stimulation with anti-IgM increased tyrosine phosphoryla-
tion levels in both wild-type and xid B cells, indicating that
the xid BCR transduced some signals (data not shown). We
failed to find any differences in mitochondrial membrane
potential (early sign of apoptosis) between wild-type and
xid B cells at this time. This suggests that the failure to acti-
vate NF-kB is unlikely to be a consequence of the apopto-
sis of xid B cells. In contrast to IgM cross-linking, CD40 li-
gation led to an increase of DNA binding activity in both
wild-type and xid B cells (Fig. 1 A).
Next, we asked if the lack of NF-kB DNA binding activ-
ity in IgM-activated xid B cells was due to reduced nuclear
NF-kB protein. We chose to analyze c-rel, as it is required
for B cell proliferation in response to anti-IgM (37). West-
ern blot analysis showed that IgM- but not CD40-induced
levels of nuclear c-rel were drastically reduced in xid B cells
(Fig. 1 B, top panel). Basal nuclear c-rel in xid B cells was
consistently less than that seen in wild-type cells. Although
CD40-mediated NF-kB/Rel DNA binding and c-rel nu-1738 BTK Links the B Cell Receptor to NF-kB Activation
clear translocation in xid B cells was slightly lower than that
in wild-type B cells, the fold inductions were similar (Fig. 1,
A and B). These initial studies suggested that BTK plays
some role, direct or indirect, in NF-kB activation.
Normal Induction of c-rel Transcript and Normal Cytoplasmic
Protein Levels in xid B Cells. The lack of IgM-mediated
NF-kB translocation and DNA binding in xid B cells could
be due to diminished amounts of total NF-kB protein.
Western blot analysis showed that the amounts of c-rel
were similar in wild-type and xid B cells under various
conditions (Fig. 2 A). In addition, we found that the level
of c-rel mRNA increased normally after anti-IgM stimula-
tion of wild-type or xid B cells (Fig. 2 B, top panel, reverse
transcriptase (RT)-PCR and bottom panel, Northern blot
analysis). This finding suggests that BCR-induced c-rel
transcription is not dependent on NF-kB, though it is
known that in vitro overexpression of c-rel can increase
constitutive activity of the c-rel promoter (51). Given the
adequate amounts of cellular c-rel transcript and protein, it
was likely that there was a failure to translocate cytoplasmic
c-rel protein to the nucleus upon IgM cross-linking.
Inefficient Degradation of IkBa in xid B Cells. In resting
cells, NF-kB/Rel transcription factors are sequestered in the
cytoplasm by IkB. There are three isoforms of IkB: a, b,
and e (52). We chose to study IkBa, a well characterized
member of the inhibitory family. In wild-type splenic B
cells, IkBa levels decreased after treatment for 4 h with anti-
IgM or CD40 ligand stimulation (Fig. 3 A). In xid B cells,
Figure 1. NF-kB/Rel DNA
binding and translocation is de-
creased in anti-IgM–activated,
btk-mutated, xid B cells. (A)
Splenic B cells from wild-type
and xid mice were cultured for
4 h in medium, F(ab9)2 anti-IgM
(10 mg/ml), or CD40 ligand (1:2
dilution), cells were harvested,
nuclear extracts prepared, and
EMSAs performed as described
in Materials and Methods. This
figure represents one of three ex-
periments. Densitometry was
performed on the upper band of
the gel shift. Addition of a cold
competitor (100-fold excess)
demonstrated the specificity of
NF-kB binding (data not
shown), as shown previously
(49). (B) Western analysis of nu-
clear c-rel expression (top panel) was conducted using 20 mg of extract prepared from wild-type or xid splenic B cells treated as described in A. Transcrip-
tion factor SP-1 served as a nuclear loading control (bottom panel). Densitometry was performed. After normalization to the loading control, it was de-
termined that anti-IgM treatment induced nuclear c-rel 4.8-fold in wild-type and 0.75-fold in xid B cells. This figure represents one of five experiments.
Figure 2. Anti-IgM induces normal
c-rel transcript levels, and amounts of
c-rel in xid B cells are normal. (A)
Wild-type and xid B splenic cells were
cultured for 4 h in medium, F(ab9)2
anti-IgM (10 mg/ml), or CD40 ligand
(1:2 dilution), and whole cell extracts
were prepared. C-rel Western blot anal-
ysis was performed using extracts pre-
pared from 5 3 105 cells. b-actin served
as a loading control. (B) Wild-type and
xid splenic B cells were cultured for 4 h
in medium, F(ab9)2 anti-IgM (10 mg/
ml), or PMA and ionomycin (30 nM
and 1 mM, respectively), and total
RNA was prepared. RT-PCR (top
panel) analysis was conducted using
primers specific for c-rel (or GaS,
which served as a loading control).
RNA samples from WEHI231 and
T220 cells served as positive and nega-
tive controls, respectively, for this assay.
Northern analysis (bottom panel) was
conducted using 10 mg of each sample. Equal loading was determined by ethidium bromide staining of 18S and 28S ribosomal bands (data not shown).
These figures represent one of three experiments.1739 Bajpai et al.
although the level of IkBa decreased in response to CD40
ligation, it did not decrease after anti-IgM cross-linking. The
IkBb protein behaved in a similar fashion (data not shown).
The most plausible explanation for maintenance of IkBa
protein levels in xid B cells despite IgM stimulation is that
the existing IkBa is not fully degraded. This possibility was
examined by 35S pulse–chase experiments. Wild-type and
xid splenic B cells were cultured with 35S-labeled cysteine
and methionine, and the experiment carried was out as de-
scribed in Materials and Methods. These 35S-labeled cells
were then cultured for 1 h with or without F(ab9)2 anti-
IgM. (We chose to stimulate cells for 1 h because we were
unable to maintain primary B cells under these labeling
conditions for longer times.) The cells were lysed, lysates
precleared, 35S-labeled IkBa immunoprecipitated (twice),
and the immunoprecipitates electrophoresed on SDS-PAGE.
After IgM activation, wild-type B cells showed a 53% de-
crease in the level of labeled IkBa. In contrast, xid B cells
consistently retained IkBa, as only a 10% decrease was de-
tected (Fig. 3 B). These data show that xid B cells failed to
fully degrade IkBa downstream of IgM cross-linking.
Reconstitution of IgM-mediated NF-kB Activity in DT40
BTK-deficient Cells. DT40, the chicken B cell line, has
been a crucial tool in the delineation of the signal transduc-
tion events after antigen receptor cross-linking (29, 53, 54).
We used DT40 cells to further investigate the role of BTK
in NF-kB activation. NF-kB–dependent luciferase re-
porter activity increased 25-fold after 4-h treatment of
Figure 3. Diminished IkBa degrada-
tion in anti-IgM–activated xid B cells.
(A) Western blot analysis of IkBa ex-
pression (top panel) was performed with
25 mg of cytoplasmic extracts prepared
from wild-type or xid splenic B cells
cultured for 4 h in medium, F(ab9)2
anti-IgM (10 mg/ml), or CD40 ligand
(1:2 dilution). b-actin served as a load-
ing control (bottom panel). This figure
represents one of three experiments. (B)
Wild-type and xid splenic B cells were
cultured with 35S-labeled cysteine and
methionine, and the experiment was
carried out as described (see text). Mean
densitometry values from three inde-
pendent experiments (shown as percent
decrease in 35S-labeled IkBa  6  SD)
were: wild-type, 55.7 6 15.1 and xid,
19.0 6 7.4.
Figure 4. Reconstitution of
IgM-mediated NF-kB activity in
BTK-deficient DT40 cells by ec-
topic expression of wild-type
(WT) BTK. (A) Transient trans-
fections of WT and BTK-defi-
cient DT40 cells were conducted
with NF-kB–driven luciferase
reporter and pRLTK constructs,
the latter serving as an internal
transfection control for the as-
say. Cells were cultured for 16 h
and then stimulated for 4 h with
medium, M4 anti-chicken IgM
(10 mg/m; light bars), or PMA
and ionomycin (30 nM and 1
mM, respectively; dark bars).
Cells were lysed and assayed as
described in Materials and Meth-
ods. For each sample, luciferase
activity was normalized to the
pRLTK internal control. The
graph shows the fold induction
of luciferase activity relative to
the luciferase activity detected in the lysates of cells cultured in medium only (5 1). This figure is representative of five experiments. (B) 10 mg of wild-
type BTK or vector (pApuro) was transiently transfected together with reporter and internal control constructs as described above (A). Null 1 Vector lane
shows background activity levels. PMA and ionomycin treatment of these cells resulted in similar induction (data not shown). Western blot analysis for
detection of BTK expression was performed using lysates (equivalent of 2.5 3 106 cells) from this assay. The anti-BTK antibody recognizes both mouse
and chicken BTK protein. The reactivity of this antibody for the different BTK species is not known, and the fraction of cells transfected was not deter-
mined the expression levels in wild-type and transfected cells cannot be compared. The fold induction values are the mean of three experiments 6 SD.1740 BTK Links the B Cell Receptor to NF-kB Activation
wild-type DT40 cells with anti-IgM (Fig. 4 A). The same
luciferase reporter construct, but lacking the three NF-kB
sites, was not induced under the same conditions (data not
shown). BTK-deficient DT40 B cells failed to induce NF-
kB activity after IgM stimulation (Fig. 4 A). Like wild-type
cells, an increase of total protein tyrosine phosphorylation
was detected after anti-IgM cross-linking of BTK-deficient
DT40 cells. In BTK-deficient DT40 cells, NF-kB–depen-
dent luciferase activity was induced by the pharmacological
reagents phorbol ester and ionomycin. Expression of BTK
in BTK-deficient cells restored the ability of membrane
IgM to activate NF-kB (Fig. 4 B). Western blot analysis
demonstrated that BTK protein was expressed in BTK-
deficient cells in these assays (Fig. 4 B).
The xid Mutation Diminishes the Ability of Ectopic BTK to
Induce NF-kB Activation. BTK is similar to Src kinases in
that it contains SH1, SH2, and SH3 domains. In addition,
it also contains a proline-rich and a unique region (together
called the Tec homology domain) and a PH domain. The
PH domain has high affinity for phosphoinositide phos-
pholipids (20) and is required for membrane localization of
the kinase. The R28C (xid) mutation of the PH domain
decreases the affinity of BTK for phospholipids and other
ligands (20, 55). The E41K (gain-of-function) mutation in
the BTK PH region increases affinity for PtdIns-3,4,5-P2
(56) and results in constitutive membrane association and
activity (57). Using ectopic expression of BTK in BTK-
deficient DT40 cells, we asked how mutations of the BTK
PH domain affected DT40 IgM–mediated NF-kB activity.
In these assays, we found that it was necessary to use higher
amounts of mutant DNA constructs to express mutant
BTK at levels comparable to wild type. It is possible that
the mutant proteins are unstable, though we have not ex-
amined this. We find that the basal NF-kB activity in-
creased ninefold when the E41K (gain-of-function) mutant
was expressed (Fig. 5). No change in basal activity was de-
tected when a similar level of the R28C (xid) mutant was
expressed. When comparable amounts of wild-type and
mutant proteins were expressed, wild-type BTK allowed a
29-fold increase in NF-kB activity. The increase in re-
porter activity with the gain-of-function and xid mutants
were 34- and 5-fold, respectively.
Discussion
NF-kB/Rel Function Is Essential for B Cell Activation.
NF-kB/Rel function is essential for B cell activation. Our
studies with murine B cells suggested that BTK function
was required for induced degradation of IkB and subse-
quent NF-kB translocation and DNA binding (Figs. 1 and
3). Mice deficient in individual NF-kB/Rel family mem-
bers and mice expressing a transdominant form of IkBa
demonstrate the importance of these transcription factors in
both CD40- and IgM-mediated B cell activation and pro-
liferation (34–36, 39). In particular, expression of a trans-
dominant form of IkBa produced a phenotype strikingly
similar to that of xid mice.
Schauer et al. (58) showed that IgM cross-linking of a B
cell line, WEHI231, failed to activate NF-kB, leading to
apoptosis. When CD40 ligand was used in combination
with anti-IgM, these cells activated NF-kB and, in turn,
blocked apoptosis (58). Thus, NF-kB proteins serve as
Figure 5. The xid (R28C) mutation decreases
BTK-dependent NF-kB activation. Transient
transfections of BTK-deficient DT40 cells were
conducted using 30 mg of vector (pApuro), 2.5, 5,
or 10 mg of wild-type BTK, or 30 mg of BTK mu-
tants, R28C, and E41K along with the NF-kB–
driven luciferase reporter construct and the pRLTK
internal control. Vector DNA was added when
necessary to allow for equivalent micrograms of
DNA to be transfected. Cells were cultured for 16 h
and then stimulated for 4 h with medium, M4 anti-
chicken IgM (10 mg/ml; black bars), or PMA and
ionomycin (30 nM and 1 mM, respectively). Cells
were lysed and assayed as described in Materials and
Methods. For each sample, luciferase activity was
normalized to the pRLTK internal control. The
graph shows the fold induction of luciferase activity
relative to the luciferase activity detected in the ly-
sates from unstimulated BTK-deficient cells trans-
fected with vector (5 1). The fold induction values
are the mean of three experiments 6 SD. PMA and
ionomycin treatment of all cells resulted in similar
fold induction values (data not shown). Western
analysis for detection of BTK expression was per-
formed using lysates (equivalent of 2.5 3 106 cells)
from this assay. The anti-BTK antibody recognizes
both mouse and chicken BTK protein. Densitome-
try analysis was performed (see Results). This figure
represents one of three Western blots.1741 Bajpai et al.
“survival” factors, most likely due to their role in the initi-
ation of specific transcription of genes that mediate sur-
vival. Previously, we showed that in contrast to wild-type
cells, there is no induction of the antiapoptotic protein Bcl-
xL in IgM-activated xid B cells (32). NF-kB is essential for
expression of Bcl-xL (59). Thus, in xid B cells, it may be
the loss of NF-kB activity that renders the B cells suscepti-
ble to apoptosis after IgM cross-linking. It is doubtful that it
is solely the loss of induced Bcl-xL that is responsible for the
xid phenotype, because xid mice expressing a Bcl-xL trans-
gene do not correct the total xid phenotype (60).
BTK Function in Developing versus Mature B Cells. In
comparison with circulating, mature B cells in wild-type
mice, the B cells in xid mice express lower levels of surface
IgD and higher levels of surface IgM (61). This observa-
tion suggests that xid B cells are in a transitional stage of B
cell development en route to full maturity (62). Thus, the
bulk of ex vivo B cells from wild-type and xid mice are at
different stages of maturity, making direct comparison of
their biochemistry problematic. To distinguish between an
indirect, developmental role and a direct role for BTK in
NF-kB activation, we turned our analysis to the trans-
formed chicken B cell line DT40. The BTK-deficient vari-
ant of DT40 cells was generated previously by homologous
recombination (29). These cells, like xid B cells, exhibit a
defect in calcium signaling after IgM receptor cross-linking
(29, 63). We found that BTK-deficient DT40 cells lacked
NF-kB activity after IgM cross-linking, corroborating our
findings with xid B cells. Expression of BTK in BTK-defi-
cient DT40 cells restored IgM-mediated NF-kB activation
(Fig. 4 B). We conclude that BTK function in mature B cells
is essential for BCR-induced NF-kB activation.
The Effect of BTK PH Domain Mutations on NF-kB Activa-
tion. The R28C mutation is known to lower the ability
of BTK to interact with and activate TFII-I and to mobilize
calcium. In particular, this mutation dramatically reduces
the affinity of BTK for the phosphoinositide phospholipid
PtdIns-3,4,5-P3 (20). Recombinant BTK PH fused to
green fluorescent protein (GFP) localized to the cell mem-
brane, as did the E41K, gain-of-function PH–GFP. The
R28C, xid PH–GFP, failed to localize to the membrane
(56). Related work by Gupta et al. showed that decreasing
the levels of PIP3, by inhibition of PI-3 kinase or mem-
brane SH2 domain–containing inositol 59-phosphatase (SHIP)
expression, led to inhibition of BTK membrane localization
and activity (21). This block in BTK activity could be
overcome when recombinant BTK was targeted to the
membrane. Collectively, these data show that membrane
localization of BTK is essential for normal function. We
now show that expression of the E41K mutant BTK in
BTK-deficient DT40 cells increased basal NF-kB activity
ninefold and with anti-IgM cross-linking 34-fold (Fig. 5).
In contrast, the equivalent BTK protein expression of the
R28C mutant had no effect on basal activity, and with anti-
Ig cross-linking only a fivefold increase in NF-kB activity
was detected. These results are consistent with previous
work showing that an intact PH domain is essential for
BTK to function, in this case to activate NF-kB.
The Role of BTK in IgM Signaling. Many studies have
identified roles for BTK in important signal transduction
events downstream of IgM that ultimately lead to cell cycle
entry and proliferation, e.g., PLC-g2 activation, calcium
mobilization, IP3 generation, cyclin activation, and Bcl-xL
upregulation (29, 30, 32, 33, 64, 65). This study identifies
another downstream event controlled by BTK, NF-kB/
IkB activation. Studies of NF-kB activation in other path-
ways, such as CD40, TNF, and IL-1, have linked IkB and
NF-kB regulation to a signaling cascade that includes the
IkB kinases mitogen-activated protein kinase kinase 1
(MEKK1) and NF-kB–inducing kinase (NIK) and TNF
receptor–associated factors (TRAFs) (42, 66–68). Previous
studies have shown that IkB is degraded and NF-kB acti-
vated as a consequence of IgM signaling, but little else is
known (43). Our laboratory is currently focusing on eluci-
dating the molecules that link BTK with IkB.
Signals Transduced by mIgM and CD40. There are many
events common to CD40 and mIgM ligation, as both lead
to activation of activator protein (AP)-1, NF-kB, nuclear
factor and activator of transcription (NF-AT), and signal
tranducers and activators of transcription (STATs), expres-
sion of Bcl-xL, and entry into cell cycle (32, 36, 69). Yet
some differences are clear. These receptors exhibit differen-
tial regulation of Fas, CD5, CD23, and mitogen-activated
protein (MAP) kinases (70–72). In addition, PKC is neces-
sary for IgM- but not CD40-induced activation of NF-kB
(36). Related work by Sen and colleagues has shown differ-
ential PKC and calcium requirements for individual NF-
kB family members downstream of the BCR (73, 74). In
this study, we show that in the absence of BTK, NF-kB
can be activated by CD40 ligation but not by IgM cross-
linking (Fig. 1). This suggests that after IgM cross-linking,
BTK, which is necessary for the phosphorylation of PLC-
g2 (29), is in turn responsible for the activation of PKC and
calcium mobilization and the activation of NF-kB.
Data from Bendall et al. showed that expression of a
transdominant IkBa blocked IgM- but not LPS-mediated
NF-kB activation (39). This study and others (75) suggest
that the several B cell activators—CD40 ligand, antigen,
and LPS—differentially regulate individual IkB family
members. In the cytoplasm of resting cells, IkB family
members interact with different NF-kB dimers (66, 76).
Whether CD40 (BTK-independent) and mIgM (BTK-
dependent) receptors activate different IkB kinases ultimately
leading to distinct gene transcription through activation of
different NF-kB dimers will be the subject of future stud-
ies. Understanding the specific control of NF-kB activation
could provide clues to the differential physiological out-
comes of these B cell activation pathways.
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